Achaogen Stock

AKAOQ

US0044491043

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	+278.79%

12/06/20	Cipla USA Inc. cancelled the acquisition of worldwide right to C-Scape of Achaogen, Inc. (OTCPK:AKAO.Q).	CI
29/05/20	Achaogen, Inc. Went Out of Business	CI

Achaogen, Inc. is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). Plazomicin is an intravenous aminoglycoside antibiotic. The Company has developed plazomicin by chemically modifying sisomicin, a naturally occurring aminoglycoside, in order to overcome common aminoglycoside resistance mechanisms. The Company has a portfolio of small molecule and antibody programs. The Company's Early Development programs include C-Scape and LpxC.

Employees

Sector

More about the company

Market Cap	639K 560K 516K 483K 906K 60.26M 925K 6.21M 2.4M 29.78M 2.4M 2.35M 103M	P/E 2017	-3.39x	P/E 2018	-0.29x
Enterprise Value	19.47M 17.07M 15.73M 14.73M 27.62M 1.84B 28.19M 189M 73.17M 908M 73.1M 71.5M 3.15B	EV / Sales 2017	28x	EV / Sales 2018	8.66x
Free-Float	-	Yield 2017 *	-	Yield 2018	-

12/06/20	Cipla USA Inc. cancelled the acquisition of worldwide right to C-Scape of Achaogen, Inc. (OTCPK:AKAO.Q).	CI
29/05/20	Achaogen, Inc. Went Out of Business	CI
29/05/20	First Amended Joint Liquidation Plan and Disclosure Statement Approved for Achaogen, Inc.	CI
22/04/20	First Amended Joint Liquidation Plan & Disclosure Statment Filed by Achaogen, Inc. and The Official Committee of Unsecured Creditors	CI
21/04/20	Disclosure Statement Approved on Interim Basis for Achaogen, Inc.	CI
30/03/20	Joint Liquidation Plan & Disclosure Statment Filed by Achaogen, Inc. and The Official Committee of Unsecured Creditors	CI
09/01/20	Motion for Asset Sale Approved for Achaogen, Inc.	CI
29/12/19	Motion for Asset Sale Filed by Achaogen, Inc.	CI
24/09/19	Final DIP Financing Approved for Achaogen, Inc.	CI
29/08/19	Motion for Exclusivity Period Extension Approved For Achaogen, Inc.	CI
13/08/19	First Motion for Exclusivity Period Extension Filed by Achaogen, Inc.	CI
30/07/19	Achaogen, Inc. Announces Management Changes	CI
23/07/19	Motion for Asset Sale Approved for Achaogen, Inc.	CI

	2017	2018
Net sales	11.18M 9.8M 9.03M 8.46M 15.86M 1.05B 16.18M 109M 42M 521M 41.96M 41.05M 1.81B	8.73M 7.65M 7.05M 6.6M 12.38M 823M 12.64M 84.78M 32.81M 407M 32.77M 32.06M 1.41B
Net income	-126M -110M -102M -95.05M -178M -11.85B -182M -1.22B -472M -5.86B -472M -461M -20.31B	-187M -164M -151M -141M -265M -17.59B -270M -1.81B -701M -8.7B -700M -685M -30.15B
Net Debt	-143M -125M -115M -108M -203M -13.47B -207M -1.39B -537M -6.66B -536M -525M -23.09B	18.83M 16.51M 15.22M 14.25M 26.71M 1.78B 27.27M 183M 70.77M 878M 70.7M 69.16M 3.04B

Achaogen Stock

Stocks

AKAOQ

US0044491043

Valuation: Achaogen

Latest news : Achaogen

Financials

Company Profile